Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis: A Retrospective Analysis of 527 Patients From the Polish Adult Leukemia Group RegistryJoanna Góra‐Tybor, Krzysztof Jamroziak, Anna Wache et al.|Clinical Lymphoma Myeloma & Leukemia|2018Cited by 11
The Outcomes of Ponatinib Therapy in Patients With Chronic Myeloid Leukemia Resistant or Intolerant to Previous Tyrosine Kinase Inhibitors, Treated in Poland Within the Donation ProgramTomasz Sacha, Olga Grzybowska‐Izydorczyk, Elżbieta Szczepanek et al.|Clinical Lymphoma Myeloma & Leukemia|2021Cited by 7
Analysis of Predictive Factors for Early Response to Ruxolitinib in 320 Patients with Myelofibrosis From the Polish Adult Leukemia Group (PALG) RegistryJoanna Góra-Tybor, Krzysztof Jamroziak, Aleksandra Gołoś et al.|Clinical Lymphoma Myeloma & Leukemia|2022Cited by 2
A Multicenter Prospective Study on Efficacy and Safety of Ponatinib in Patients with Chronic Myeloid Leukemia Resistant or Intolerant to Previous Therapy: A 3-Year ReportTomasz Sacha, Olga Grzybowska‐Izydorczyk, Elżbieta Szczepanek et al.|Blood|2020Cited by 1
Analysis of Predictive Factors for Early Response to Ruxolitinib in 266 Patients with Myelofibrosis from the Polish Adult Leukemia Group (PALG) RegistryJoanna Góra‐Tybor, Krzysztof Jamroziak, Aleksandra Gołoś et al.|Blood|2019Cited by 0